BioSpace News Archive

Prelude Therapeutics Inc. today announced that Kris Vaddi, PhD, Chief Executive Officer, will participate in a fireside chat at the 4th Annual Evercore ISI HealthCONx Conference taking place on Wednesday, December 1, 2021 at 9:15 am ET.

Medtronic plc (NYSE:MDT) today announced financial results for its second quarter of fiscal year 2022, which ended October 29, 2021.

Calyxt, Inc. today announced that management will present at the 2021 Canaccord Genuity AgriFood Tech Innovation Virtual Forum.

Qilian International Holding Group Limited today announced that Gan Di Xin® and Qilian Shan® Oxytetracycline, products of the Company’s subsidiary, Gansu Qilianshan Pharmaceutical Co., Ltd. (“Gansu QLS”), have been included in the List for Development of Leading Enterprises with Large Varieties and Brands of Pharmaceuticals of Gansu Province (the “List”).

Merchants utilizing Shift4Shop’s turnkey e-commerce platform can help their customers’ online purchases mean more this holiday shopping season. Customers can now donate to St. Jude Children’s Research Hospital.

Kura Oncology, Inc., a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, announced that Troy Wilson, Ph.D., J.D., President and Chief Executive Officer, is scheduled to participate in two upcoming virtual investor conferences.

Novocure (NASDAQ: NVCR) announced today it will participate in two upcoming investor conferences.

Cybin Inc. today announced it has awarded a grant for the first psychedelic treatment clinic at Lenox Hill Hospital, part of Northwell Health, to serve marginalized and underserved communities on the Upper East Side of Manhattan, New York.

KAHR, a cancer immunotherapy company developing novel multifunctional immune-recruitment proteins, today announced it will host a virtual key opinion leader (KOL) webinar on the potential of CD47 therapeutics for the treatment of solid tumor and hematologic malignancies on Thursday, December 2, 2021, from 4:30 pm to 5:30 pm ET.

Rubius Therapeutics, Inc. (Nasdaq: RUBY), a clinical-stage biopharmaceutical company that is genetically engineering red blood cells to create an entirely new class of cellular medicines called Red Cell Therapeutics™ for the treatment of cancer and autoimmune diseases, today announced that Pablo J. Cagnoni, M.D., President and Chief Executive Officer, will participate in a fireside chat at the Evercore ISI 4th Annual HealthCONx Conference.